The Role and Mechanism of CRL4 E3 Ubiquitin Ligase in Cancer and Its Potential Therapy Implications

Overview

Journal Oncotarget

Specialty Oncology

Date 2015 Oct 14

PMID 26460955

Citations 30

Authors

Youzhou Sang

Fan Yan

Xiubao Ren

Affiliations

Soon will be listed here.

Abstract

CRLs (Cullin-RING E3 ubiquitin ligases) are the largest E3 ligase family in eukaryotes, which ubiquitinate a wide range of substrates involved in cell cycle regulation, signal transduction, transcriptional regulation, DNA damage response, genomic integrity, tumor suppression and embryonic development. CRL4 E3 ubiquitin ligase, as one member of CRLs family, consists of a RING finger domain protein, cullin4 (CUL4) scaffold protein and DDB1-CUL4 associated substrate receptors. The CUL4 subfamily includes two members, CUL4A and CUL4B, which share extensively sequence identity and functional redundancy. Aberrant expression of CUL4 has been found in a majority of tumors. Given the significance of CUL4 in cancer, understanding its detailed aspects of pathogenesis of human malignancy would have significant value for the treatment of cancer. Here, the work provides an overview to address the role of CRL4 E3 ubiquitin ligase in cancer development and progression, and discuss the possible mechanisms of CRL4 ligase involving in many cellular processes associated with tumor. Finally, we discuss its potential value in cancer therapy.

Citing Articles

Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer.

Claridge S, Nath S, Baum A, Farias R, Cavallo J, Rizvi N Clin Transl Med. 2025; 15(2):e70078.

PMID: 39856363 PMC: 11761363. DOI: 10.1002/ctm2.70078.

The role of p53 in male infertility.

Li J, Huang X, Luo L, Sun J, Guo Q, Yang X Front Endocrinol (Lausanne). 2024; 15:1457985.

PMID: 39469578 PMC: 11513281. DOI: 10.3389/fendo.2024.1457985.

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity.

Xu D, Yin S, Shu Y NPJ Precis Oncol. 2024; 8(1):133.

PMID: 38879686 PMC: 11180135. DOI: 10.1038/s41698-024-00627-5.

CUL4A Ubiquitin Ligase Is an Independent Predictor of Overall Survival in Pancreatic Adenocarcinoma.

Tavlas P, Nikou S, Geramoutsou C, Bosgana P, Tsaniras S, Melachrinou M Cancer Genomics Proteomics. 2024; 21(2):166-177.

PMID: 38423594 PMC: 10905276. DOI: 10.21873/cgp.20438.

SMC5/6 Promotes Replication Fork Stability via Negative Regulation of the COP9 Signalosome.

Xu M, Jordan P Int J Mol Sci. 2024; 25(2).

PMID: 38256025 PMC: 10815603. DOI: 10.3390/ijms25020952.

References

Karakaidos P, Taraviras S, Vassiliou L, Zacharatos P, Kastrinakis N, Kougiou D . Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability--evidence of E2F-1 transcriptional.... Am J Pathol. 2004; 165(4):1351-65. PMC: 1618634. DOI: 10.1016/S0002-9440(10)63393-7. View

Soucy T, Smith P, Milhollen M, Berger A, Gavin J, Adhikari S . An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009; 458(7239):732-6. DOI: 10.1038/nature07884. View

Viola M, Fromowitz F, Oravez S, Deb S, Schlom J . ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med. 1985; 161(5):1213-8. PMC: 2187613. DOI: 10.1084/jem.161.5.1213. View

Cang Y, Zhang J, Nicholas S, Bastien J, Li B, Zhou P . Deletion of DDB1 in mouse brain and lens leads to p53-dependent elimination of proliferating cells. Cell. 2006; 127(5):929-40. DOI: 10.1016/j.cell.2006.09.045. View

Groisman R, Kuraoka I, Chevallier O, Gaye N, Magnaldo T, Tanaka K . CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome. Genes Dev. 2006; 20(11):1429-34. PMC: 1475755. DOI: 10.1101/gad.378206. View

Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M . High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013; 161(5):695-700. DOI: 10.1111/bjh.12338. View

Yasui K, Arii S, Zhao C, Imoto I, Ueda M, Nagai H . TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology. 2002; 35(6):1476-84. DOI: 10.1053/jhep.2002.33683. View

Lopez-Lago M, Okada T, Murillo M, Socci N, Giancotti F . Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol. 2009; 29(15):4235-49. PMC: 2715795. DOI: 10.1128/MCB.01578-08. View

Higgins J, Pucilowska J, Lombardi R, Rooney J . A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology. 2004; 63(10):1927-31. PMC: 1201536. DOI: 10.1212/01.wnl.0000146196.01316.a2. View

10.

Ito T, Ando H, Handa H . Teratogenic effects of thalidomide: molecular mechanisms. Cell Mol Life Sci. 2011; 68(9):1569-79. PMC: 11114848. DOI: 10.1007/s00018-010-0619-9. View

11.

Lyapina S, Correll C, Kipreos E, Deshaies R . Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein. Proc Natl Acad Sci U S A. 1998; 95(13):7451-6. PMC: 22647. DOI: 10.1073/pnas.95.13.7451. View

12.

Huang S, Lin C, Lin H, Yao M, Tang J, Wu S . Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014; 93(8):1371-80. PMC: 4082140. DOI: 10.1007/s00277-014-2063-7. View

13.

Shi X, Kachirskaia I, Yamaguchi H, West L, Wen H, Wang E . Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell. 2007; 27(4):636-46. PMC: 2693209. DOI: 10.1016/j.molcel.2007.07.012. View

14.

Thoreen C, Kang S, Chang J, Liu Q, Zhang J, Gao Y . An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem. 2009; 284(12):8023-32. PMC: 2658096. DOI: 10.1074/jbc.M900301200. View

15.

Kim W, Sharpless N . The regulation of INK4/ARF in cancer and aging. Cell. 2006; 127(2):265-75. DOI: 10.1016/j.cell.2006.10.003. View

16.

He T, Sparks A, Rago C, Hermeking H, Zawel L, DA COSTA L . Identification of c-MYC as a target of the APC pathway. Science. 1998; 281(5382):1509-12. DOI: 10.1126/science.281.5382.1509. View

17.

Tian J, He H, Lei G . Wnt/β-catenin pathway in bone cancers. Tumour Biol. 2014; 35(10):9439-45. DOI: 10.1007/s13277-014-2433-8. View

18.

Sugasawa K, Okuda Y, Saijo M, Nishi R, Matsuda N, Chu G . UV-induced ubiquitylation of XPC protein mediated by UV-DDB-ubiquitin ligase complex. Cell. 2005; 121(3):387-400. DOI: 10.1016/j.cell.2005.02.035. View

19.

Sivaprasad U, Machida Y, Dutta A . APC/C--the master controller of origin licensing?. Cell Div. 2007; 2:8. PMC: 1810247. DOI: 10.1186/1747-1028-2-8. View

20.

Dong J, Wang X, Yao J, Li G, Li X . Decreased CUL4B expression inhibits malignant proliferation of glioma in vitro and in vivo. Eur Rev Med Pharmacol Sci. 2015; 19(6):1013-21. View